GBO-006-1

News alerts, weekly reports and conference planners

Company:

Traws Pharma

Drug class:

PLK2 inhibitor

‹

›

3ms

Integrative analysis of polo-like kinase family identifies a prognostic signature and validates PLK2 as a therapeutic target in glioma. (PubMed, Transl Cancer Res)

Our study highlights the prognostic value of the PLK gene family in glioma and identifies PLK2 as a promising therapeutic target. The PLK2 inhibitor ON1231320 shows potential as an anti-GBM agent and warrants further investigation in preclinical and clinical studies.

3 months ago

Journal

PLK1 (Polo Like Kinase 1) • PLK2 (Polo Like Kinase 2)

GBO-006-1

1year

Genome-Wide Screening in Haploid Stem Cells Reveals Synthetic Lethality Targeting MLH1 and TP53 Deficient Tumours. (PubMed, Cell Prolif)

The specific effects of SR1848, which inhibits NR5A2, ON1231320 or BI2536, which inhibits PLK2, and blebbistatin, which inhibits MYH10, were further validated in cancer cell lines. Finally, animal studies with CCL xenografts showed the selective effect of the small molecule BI2536 on MLH1-null tumours and of blebbistatin on TP53-mutated tumours. Thus, demonstrating their potential for personalised medicine, and the robustness of genetic screening in haploid hESCs in the context of cancer therapeutics.

1 year ago

Journal

TP53 (Tumor protein P53) • MLH1 (MutL homolog 1) • PLK2 (Polo Like Kinase 2) • NR5A2 (Nuclear Receptor Subfamily 5 Group A Member 2)

TP53 mutation • MLH1 mutation

BI2536 • GBO-006-1

almost4years

Polo-like kinases as potential targets and PLK2 as a novel biomarker for the prognosis of human glioblastoma. (PubMed, Aging (Albany NY))

In glioma cells, ON1231320 has anticancer effects. Finally, a summary of PLK inhibitors is presented, along with projections for future progress.

almost 4 years ago

Journal

PLK1 (Polo Like Kinase 1) • PLK2 (Polo Like Kinase 2)

GBO-006-1